A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2018
At a glance
- Drugs BL 8040 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms COMBAT
- Sponsors BioLineRx
- 20 Jan 2018 Results (n=32) assessing pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, were presented at the 2018 Gastrointestinal Cancers Symposium.
- 17 Jan 2018 According to a BioLineRx media release, data will be presented at the ASCO 2018 Gastrointestinal Cancers Symposium.
- 17 Jan 2018 Results published in the BioLineRx Media Release